Spectral AI FY2024 EPS Forecast Lifted by Northland Capmk

Spectral AI, Inc. (NASDAQ:MDAI) – Equities research analysts at Northland Capmk raised their FY2024 earnings estimates for shares of Spectral AI in a research note issued on Tuesday, December 3rd. Northland Capmk analyst C. Byrnes now forecasts that the company will post earnings of ($0.48) per share for the year, up from their previous estimate of ($0.67). Northland Capmk has a “Strong-Buy” rating on the stock. The consensus estimate for Spectral AI’s current full-year earnings is ($0.54) per share. Northland Capmk also issued estimates for Spectral AI’s Q4 2024 earnings at ($0.10) EPS.

Other equities research analysts also recently issued research reports about the company. HC Wainwright reaffirmed a “buy” rating and set a $3.50 target price on shares of Spectral AI in a report on Tuesday, August 13th. Northland Securities started coverage on shares of Spectral AI in a report on Monday, August 12th. They issued an “outperform” rating and a $6.00 price objective on the stock.

Spectral AI Price Performance

Shares of MDAI opened at $2.09 on Thursday. The company’s fifty day moving average price is $1.37 and its 200-day moving average price is $1.51. Spectral AI has a 1-year low of $0.82 and a 1-year high of $3.72. The firm has a market capitalization of $38.85 million, a PE ratio of -3.22 and a beta of 0.64.

Hedge Funds Weigh In On Spectral AI

A hedge fund recently bought a new stake in Spectral AI stock. Virtu Financial LLC acquired a new stake in Spectral AI, Inc. (NASDAQ:MDAI) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 17,830 shares of the company’s stock, valued at approximately $38,000. Virtu Financial LLC owned approximately 0.10% of Spectral AI as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 67.08% of the company’s stock.

About Spectral AI

Spectral AI, Inc, an artificial intelligence (AI) company, focuses on developing predictive medical diagnostics in the United States. The company develops medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers.